Department of Drug Sciences, Section of Pharmacology, University of Pavia, Pavia, Italy.
Ensemble Hospitalier de la Cote - Centre Lemanique d'antalgie et Neuromodulation, Morges, Switzerland.
Curr Neuropharmacol. 2024;22(1):53-64. doi: 10.2174/1570159X21666230807103642.
A majority of older patients suffer from neuropathic pain (NP) that significantly alters their daily activities and imposes a significant burden on health care. Multiple comorbidities and the risk of polypharmacy in the elderly make it challenging to determine the appropriate drug, dosage, and maintenance of therapy. Age-dependent processes play a contributing role in neuropathy given that diabetic neuropathy (DN) is the most common form of neuropathy. This narrative review is mainly focused on the drug treatment approach for neuropathy-associated pain in aged people including both drugs and dietary supplements, considering the latter as add-on mechanism-based treatments to increase the effectiveness of usual treatments by implementing their activity or activating other analgesic pathways. On one hand, the limited clinical studies assessing the effectiveness and the adverse effects of existing pain management options in this age segment of the population (> 65), on the other hand, the expanding global demographics of the elderly contribute to building up an unresolved pain management problem that needs the attention of healthcare providers, researchers, and health authorities as well as the expansion of the current therapeutic options.
大多数老年患者患有神经病理性疼痛 (NP),这会显著改变他们的日常活动,并对医疗保健造成重大负担。老年人的多种合并症和多药治疗的风险使得确定适当的药物、剂量和治疗维持变得具有挑战性。与年龄相关的过程在神经病变中起着一定的作用,因为糖尿病性神经病变 (DN) 是最常见的神经病变形式。本叙述性综述主要关注老年人神经病变相关疼痛的药物治疗方法,包括药物和膳食补充剂,考虑到后者是基于机制的附加治疗方法,通过实施其活性或激活其他镇痛途径来提高常规治疗的效果。一方面,评估现有疼痛管理方案在这一年龄段人群(>65 岁)中的有效性和不良反应的临床研究有限,另一方面,老年人全球人口统计学的不断扩大导致了未解决的疼痛管理问题,需要医疗保健提供者、研究人员和卫生当局的关注,以及当前治疗选择的扩展。